SpacePharma is proud to announce its participation in the 3rd Health from Space International Congress, taking place on April 2-3, 2025, at the Palais des Festivals in Cannes, France. This unique event aims to bridge Earth-based markets with the opportunities offered by space, bringing together global leaders in space medicine and life sciences. SpacePharma is excited to contribute to discussions on leveraging space environments to transform health solutions on Earth.

SpacePharma has been selected for the prestigious European Innovation Council (EIC) Accelerator program, receiving significant funding to advance SPACTORY, the first fully automated microgravity space factory. SPACTORY aims to transform pharmaceutical manufacturing by leveraging the unique environment of space to produce purer, more stable compounds, including monoclonal antibodies, which are critical for treating diseases like cancer. This achievement highlights SpacePharma’s pioneering role in space-based biotechnology, positioning the company to drive innovation, economic growth, and global impact in the years ahead.

SpacePharma's CEO Yossi Yamin participated in Wilson Sonsini's webinar on the future of medicine and biotechnology in Space. Together with leading experts in the industry, a discussion was held on how space and microgravity can revolutionize medicine and biotechnology and the key considerations for companies in the sector. A recording of the webinar is available behind the following link.

SpacePharma has established its European office at the International Space University (ISU) central campus in Strasbourg, France, leveraging the university's notoriety and its access to the international space community.

‍

The Guardian explores how experiments in space may revolutionize biomedical research, particularly in protein crystallization, stem cell cultivation and disease study. SpacePharma is sending experiments to the International Space Station (ISS) to conduct studies in an environment uninfluenced by Earth's gravity, with initial results hinting at potentially ground-breaking medical advancements.

SpacePharma is setting up its European headquarters in the Innovation Park of Strasbourg, Eastern France. In addition, SpacePharma is part of the organizing committee for the international "Health from Space" congress taking place in Cannes from February 15 to 16, 2023, aiming to explore the largely untapped potential of space in the health and pharmaceutical sectors.

‍

Read about how SpacePharma is “turning science fiction into science fact” and how it is helping improve the health of those on Earth by sending experiments into space.

SpacePharma has successfully launched its miniature lab for the fifth time to the International Space Station (ISS) on the Axiom-1 mission using SpaceX's Falcon9 rocket. In this interview with the Jerusalem Post, SpacePharma CEO Mr. Yossi Yamin discusses the significance of performing experiments in microgravity, the complexities of space logistics, and the future of medicine and pharmacology in space.

‍

On April 8th, 2022, SpacePharma, in collaboration with Aleph Farms, Amorphical, and CADW Therapeutics, launched the first all-private Axiom Space mission to the ESA ISS Columbus Module, to investigate the effects of microgravity on in-situ cultivated meat, bone and muscle cell growth, and DNA damage response respectively.

‍

Listen to the podcast interview with SpacePharma CEO, Mr. Yossi Yamin, about SpacePharma’s cutting edge remote controlled space labs.

Click the link to watch:

Swiss Pavilion - Vivatech - SpacePharma

‍

CB Insights has chosen SpacePharma as 1 of the 48 most innovative, game-changing companies in the world! Check it out: CB Insights - Game Changers 2021

"Spacepharma has developed a laboratory which can be used in space to conduct experiments in microgravity at a fraction of the cost of traditional launchers."

Watch the ILTV interview with SpacePharma CEO, Mr. Yossi Yamin

Israel’s SpacePharma is pioneering the ‘Made in Space’ revolution

Article by Calcalist CTech about how SpacePharma is revolutionizing space-based science by creating miniaturized labs that can conduct experiments in microgravity conditions, potentially opening the door for off-planet pharmaceutical production. The company's groundbreaking technology promises significant advancements in life science, foodtech, chemicals, materials, and more, offering cost-effective and innovative solutions for research and production in space.

‍

‍

ENNEDY SPACE CENTER (FL), October 24, 2018 –The International Space Station (ISS) U.S. National Laboratory, the National Center for Advancing Translational Sciences (NCATS) and the National Institute of Biomedical Imaging and Bioengineering (NIBIB), today announced a series of project awards stemming from a funding opportunity on human physiology and disease onboard the orbiting laboratory.

SpacePharma SA selected ISIS – Innovative Solutions In Space B.V. to build the platform and integrate the payload for their next mission, DIDO-3, with support for satellite commissioning after launch. The agreement is a continuation of a fruitful cooperation to realize SpacePharma’s previous satellite, named DIDO-2, which was the proof of concept mission to test miniaturized end-to-end pharmaceutical laboratory in space, allowing microgravity conditions.

NCATS has partnered with the Center for the Advancement of Science in Space (CASIS) to collaborate on refining tissue chip technology for biomedical research use at the International Space Station U.S. National Laboratory (ISS-NL).

Huge honor! SpacePharma has been selected for Red Herring's top 100 companies in North America!

Spacepharma specializes in medical experiments in microgravity, that is approximate weightlessness. This can accelerate research processes for new drugs or vaccines. In weightlessness, crystals, proteins, liquids and human genomes react differently than on Earth.

Fast Company's Top 10 lists recognize pioneering companies across 36 categories, from artificial intelligence to wellness. More than three dozen Fast Company editors, reporters, and contributors surveyed thousands of companies to create these lists. The ranking recognizes companies that exemplify the best in business and innovation in their respective fields.

On the sidelines of the Ilan Ramon conference in Tel Aviv on space, Italy and Israel signed an agreement to enable the creation of a joint micro-gravity laboratory. The announcement was made by the Italian embassy, which noted that - in February 2019 - there may be the launch from an Italian-produced Vega shuttle of a space module the size of an electric bicycle battery made by the Israel-based company SpacePharma.

Watch the video!

Peoples Awards 2017. Rankings - Leaders & Companies

NewSpace People - SpacePharma Ranked 11 out of Top 1,000 companies in 2017

‍

Florida Governor, Rick Scott, honored SpacePharmas CEO & Founder a Golden Business medal for SpacePharma's activity in Florida.

Docking of the OA8 with SpacePharma's Nexus Lab inside to the ISS

‍

Spacepharma's Nexus Launch to the ISS

‍

PRESS RELEASE CBInsights - July 6 2017, Frontier Health: 11 Startups Pioneering VR, Drones, Space Tech, Brain-Hacking, And More To Advance Medical Care.

PRESS RELEASE The Washington Post - March 18 2017 A tissue-box-size lab is circling the Earth conducting tiny experiments.

SpacePharma establishes communications with its first nanosatellite.

Company inching closer to offering scientific community a third viable platform for affordable access to microgravity

COURGENAY, Switzerland – Officials with SpacePharma SA, a world leader in providing simplified, high-value microgravity services, today issued the following statement regarding its orbiting nanosatellite, DIDO, which was one of 104 satellites launched on Feb. 15 aboard Indian Space Research Organization’s PSLV-C37 rocket:

“Today, we established a successful communications link with DIDO, SpacePharma’s nanosatellite equipped with mGnify, our proprietary miniaturized, end-to-end laboratory that allows researchers to remotely control vital scientific experiments anywhere from Earth,” said Yossi Yamin, founder of SpacePharma SA. “Everything on board DIDO appears to be working properly. We look forward to fully activating mGnify in the coming weeks and launching a suite of scientific experiments for our research customers. At that point, we will officially have three viable platforms – ground simulators, parabolic flights and nanosatellites – for achieving affordable access to microgravity.”

SpacePharma SA completes first step in securing new platform for affordable access to microgravity

BASEL, Switzerland – Officials with SpacePharma SA, a world leader in providing simplified, high-value microgravity services, today issued the following statement on the successful launch of the Indian Space Research Organisation’s PSLV-C37 rocket, which carried SpacePharma’s DIDO nanosatellite – one of 101 nanosatellites on board:

“Today’s launch marks an important milestone in SpacePharma’s quest to offer researchers affordable access to microgravity through multiple platforms,” said Yossi Yamin, founder of SpacePharma SA. “The rocket carried our newest platform, a nanosatellite named DIDO. This nanosatellite is equipped with mGnify, our proprietary miniaturized, end-to-end laboratory that allows researchers to remotely control vital scientific experiments anywhere from Earth. We plan to establish communication with DIDO in a few days, which then sets the stage for full activation of mGnify shortly thereafter. Once fully activated, our science customers will be able to fully control their on-board experiments and receive valuable scientific data directly on the device of their choice.”

‍

10... 9... 8...

We're launching today! DIDO - our satellite, has been placed inside the Indian rocket PSLV-C37. In a few hours it'll be sent off to space together with a record number of 100 other nano-satellites.

‍

On October 22, our team has successfuly flown a few microgravity experiments on-board a parabolic flight which took place in Switzerland. Not only did interesting science run in our miniturized lab, but we have also demonstrated some of the new technology which will be part of our future generation lab.

SpacePharma has opened offices in Palo Alto, California. Check out our press release

Geektime has selected SpacePharma as 1 of 10 space companies to watch in 2016/2017 Beyond SpaceX: 10 space companies to watch in 2016 & 2017

SpacePharma is proud to announce its participation in the 3rd Health from Space International Congress, taking place on April 2-3, 2025, at the Palais des Festivals in Cannes, France. This unique event aims to bridge Earth-based markets with the opportunities offered by space, bringing together global leaders in space medicine and life sciences. SpacePharma is excited to contribute to discussions on leveraging space environments to transform health solutions on Earth.

SpacePharma has been selected for the prestigious European Innovation Council (EIC) Accelerator program, receiving significant funding to advance SPACTORY, the first fully automated microgravity space factory. SPACTORY aims to transform pharmaceutical manufacturing by leveraging the unique environment of space to produce purer, more stable compounds, including monoclonal antibodies, which are critical for treating diseases like cancer. This achievement highlights SpacePharma’s pioneering role in space-based biotechnology, positioning the company to drive innovation, economic growth, and global impact in the years ahead.

SpacePharma's CEO Yossi Yamin participated in Wilson Sonsini's webinar on the future of medicine and biotechnology in Space. Together with leading experts in the industry, a discussion was held on how space and microgravity can revolutionize medicine and biotechnology and the key considerations for companies in the sector. A recording of the webinar is available behind the following link.

SpacePharma has established its European office at the International Space University (ISU) central campus in Strasbourg, France, leveraging the university's notoriety and its access to the international space community.

‍

The Guardian explores how experiments in space may revolutionize biomedical research, particularly in protein crystallization, stem cell cultivation and disease study. SpacePharma is sending experiments to the International Space Station (ISS) to conduct studies in an environment uninfluenced by Earth's gravity, with initial results hinting at potentially ground-breaking medical advancements.

SpacePharma is setting up its European headquarters in the Innovation Park of Strasbourg, Eastern France. In addition, SpacePharma is part of the organizing committee for the international "Health from Space" congress taking place in Cannes from February 15 to 16, 2023, aiming to explore the largely untapped potential of space in the health and pharmaceutical sectors.

‍

Read about how SpacePharma is “turning science fiction into science fact” and how it is helping improve the health of those on Earth by sending experiments into space.

SpacePharma has successfully launched its miniature lab for the fifth time to the International Space Station (ISS) on the Axiom-1 mission using SpaceX's Falcon9 rocket. In this interview with the Jerusalem Post, SpacePharma CEO Mr. Yossi Yamin discusses the significance of performing experiments in microgravity, the complexities of space logistics, and the future of medicine and pharmacology in space.

‍

On April 8th, 2022, SpacePharma, in collaboration with Aleph Farms, Amorphical, and CADW Therapeutics, launched the first all-private Axiom Space mission to the ESA ISS Columbus Module, to investigate the effects of microgravity on in-situ cultivated meat, bone and muscle cell growth, and DNA damage response respectively.

‍

Listen to the podcast interview with SpacePharma CEO, Mr. Yossi Yamin, about SpacePharma’s cutting edge remote controlled space labs.

Click the link to watch:

Swiss Pavilion - Vivatech - SpacePharma

‍

CB Insights has chosen SpacePharma as 1 of the 48 most innovative, game-changing companies in the world! Check it out: CB Insights - Game Changers 2021

"Spacepharma has developed a laboratory which can be used in space to conduct experiments in microgravity at a fraction of the cost of traditional launchers."

Watch the ILTV interview with SpacePharma CEO, Mr. Yossi Yamin

Israel’s SpacePharma is pioneering the ‘Made in Space’ revolution

Article by Calcalist CTech about how SpacePharma is revolutionizing space-based science by creating miniaturized labs that can conduct experiments in microgravity conditions, potentially opening the door for off-planet pharmaceutical production. The company's groundbreaking technology promises significant advancements in life science, foodtech, chemicals, materials, and more, offering cost-effective and innovative solutions for research and production in space.

‍

‍

ENNEDY SPACE CENTER (FL), October 24, 2018 –The International Space Station (ISS) U.S. National Laboratory, the National Center for Advancing Translational Sciences (NCATS) and the National Institute of Biomedical Imaging and Bioengineering (NIBIB), today announced a series of project awards stemming from a funding opportunity on human physiology and disease onboard the orbiting laboratory.

SpacePharma SA selected ISIS – Innovative Solutions In Space B.V. to build the platform and integrate the payload for their next mission, DIDO-3, with support for satellite commissioning after launch. The agreement is a continuation of a fruitful cooperation to realize SpacePharma’s previous satellite, named DIDO-2, which was the proof of concept mission to test miniaturized end-to-end pharmaceutical laboratory in space, allowing microgravity conditions.

NCATS has partnered with the Center for the Advancement of Science in Space (CASIS) to collaborate on refining tissue chip technology for biomedical research use at the International Space Station U.S. National Laboratory (ISS-NL).

Huge honor! SpacePharma has been selected for Red Herring's top 100 companies in North America!

Spacepharma specializes in medical experiments in microgravity, that is approximate weightlessness. This can accelerate research processes for new drugs or vaccines. In weightlessness, crystals, proteins, liquids and human genomes react differently than on Earth.

Fast Company's Top 10 lists recognize pioneering companies across 36 categories, from artificial intelligence to wellness. More than three dozen Fast Company editors, reporters, and contributors surveyed thousands of companies to create these lists. The ranking recognizes companies that exemplify the best in business and innovation in their respective fields.

On the sidelines of the Ilan Ramon conference in Tel Aviv on space, Italy and Israel signed an agreement to enable the creation of a joint micro-gravity laboratory. The announcement was made by the Italian embassy, which noted that - in February 2019 - there may be the launch from an Italian-produced Vega shuttle of a space module the size of an electric bicycle battery made by the Israel-based company SpacePharma.

Watch the video!

Peoples Awards 2017. Rankings - Leaders & Companies

NewSpace People - SpacePharma Ranked 11 out of Top 1,000 companies in 2017

‍

Florida Governor, Rick Scott, honored SpacePharmas CEO & Founder a Golden Business medal for SpacePharma's activity in Florida.

Docking of the OA8 with SpacePharma's Nexus Lab inside to the ISS

‍

Spacepharma's Nexus Launch to the ISS

‍

PRESS RELEASE CBInsights - July 6 2017, Frontier Health: 11 Startups Pioneering VR, Drones, Space Tech, Brain-Hacking, And More To Advance Medical Care.

PRESS RELEASE The Washington Post - March 18 2017 A tissue-box-size lab is circling the Earth conducting tiny experiments.

SpacePharma establishes communications with its first nanosatellite.

Company inching closer to offering scientific community a third viable platform for affordable access to microgravity

COURGENAY, Switzerland – Officials with SpacePharma SA, a world leader in providing simplified, high-value microgravity services, today issued the following statement regarding its orbiting nanosatellite, DIDO, which was one of 104 satellites launched on Feb. 15 aboard Indian Space Research Organization’s PSLV-C37 rocket:

“Today, we established a successful communications link with DIDO, SpacePharma’s nanosatellite equipped with mGnify, our proprietary miniaturized, end-to-end laboratory that allows researchers to remotely control vital scientific experiments anywhere from Earth,” said Yossi Yamin, founder of SpacePharma SA. “Everything on board DIDO appears to be working properly. We look forward to fully activating mGnify in the coming weeks and launching a suite of scientific experiments for our research customers. At that point, we will officially have three viable platforms – ground simulators, parabolic flights and nanosatellites – for achieving affordable access to microgravity.”

SpacePharma SA completes first step in securing new platform for affordable access to microgravity

BASEL, Switzerland – Officials with SpacePharma SA, a world leader in providing simplified, high-value microgravity services, today issued the following statement on the successful launch of the Indian Space Research Organisation’s PSLV-C37 rocket, which carried SpacePharma’s DIDO nanosatellite – one of 101 nanosatellites on board:

“Today’s launch marks an important milestone in SpacePharma’s quest to offer researchers affordable access to microgravity through multiple platforms,” said Yossi Yamin, founder of SpacePharma SA. “The rocket carried our newest platform, a nanosatellite named DIDO. This nanosatellite is equipped with mGnify, our proprietary miniaturized, end-to-end laboratory that allows researchers to remotely control vital scientific experiments anywhere from Earth. We plan to establish communication with DIDO in a few days, which then sets the stage for full activation of mGnify shortly thereafter. Once fully activated, our science customers will be able to fully control their on-board experiments and receive valuable scientific data directly on the device of their choice.”

‍

10... 9... 8...

We're launching today! DIDO - our satellite, has been placed inside the Indian rocket PSLV-C37. In a few hours it'll be sent off to space together with a record number of 100 other nano-satellites.

‍

On October 22, our team has successfuly flown a few microgravity experiments on-board a parabolic flight which took place in Switzerland. Not only did interesting science run in our miniturized lab, but we have also demonstrated some of the new technology which will be part of our future generation lab.

SpacePharma has opened offices in Palo Alto, California. Check out our press release

Geektime has selected SpacePharma as 1 of 10 space companies to watch in 2016/2017 Beyond SpaceX: 10 space companies to watch in 2016 & 2017